Early detection and treatment of cardiac dysfunction in cancer patients improve overall survival

The objective of this study was to analyze the impact of the early detection and treatment of cardiac dysfunction on overall survival in cancer patients.

A retrospective analysis was conducted on clinical data from 60 cancer patients with concurrent cardiac dysfunction, admitted between January 2020 and November 2022. Patients were divided into an early treatment group (n=35), where treatment began within 24 h of diagnosis, and a late treatment group (n=25), where treatment started after 24 h. The clinical efficacy, early diastolic filling velocity, fractional shortening, left ventricular ejection fraction, and Quality of Life Questionnaire-Core 30 scores were compared before and after treatment. Adverse reactions, cardiovascular events, and 1-year survival rates were also evaluated.

The early treatment group showed higher total effective and survival rates compared to the late group (p<0.05). The post-treatment levels of early diastolic filling velocity, fractional shortening, left ventricular ejection fraction, and Quality of Life Questionnaire-Core 30 scores were statistically significantly higher in the early group (p<0.05), with no notable differences in adverse reactions (p>0.05). Kaplan-Meier analysis revealed a statistically significantly higher 1-year survival probability in the early treatment group (log-rank p=0.02).

Early detection and treatment of cardiac dysfunction in cancer patients can improve treatment efficacy and survival rate, better improve cardiac function and quality of life, and reduce the occurrence of adverse cardiovascular events.